CellCentric approached Aptus Clinical to assist them in designing their First in Human (FiH) study for their lead project, a small molecule inhibitor of p300/CBP

Aptus Clinical convened a multi-disciplinary panel of medical, scientific and technical experts to ensure CellCentric received industry-leading input into the development of an innovative clinical plan to support the development of their lead oncology asset

A comprehensive clinical plan for a FiH study was produced. This included:

• Study Design Concept, including endpoints, patient population/numbers, outcome variables and statistical considerations
• Go/no-go triggers for starting additional modules
• Phase II study options, including combination strategies and additional patient segments
• High level time and study budget estimates
• Competitor landscape reports for mode of action and tumour types of interest

CellCentric was delighted with how the Aptus Clinical team partnered seamlessly with their small in-house team to produce a plan that provided the insights they needed to confidently enter discussions with their key stakeholders and investors